PUBLICATIONS
2024
Tabariès S, Robert A, Marcil A, Ling B, Acchione M, Lippens J, Pagé M, Fortin A, Meury L, Coutu M, Annis MG, Girondel C, Navarre J, Jaramillo M, Moraitis AN, Siegel PM. Anti-Claudin-2 Antibody-Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis. Mol Cancer Ther. 2024 Jun 21. doi: 10.1158/1535-7163.MCT-23-0393. Online ahead of print.PMID: 38902871
Vonniessen B, Tabariès S, Siegel PM. Antibody-mediated targeting of Claudins in cancer. Front Oncol. 2024 Feb 2;14:1320766. doi: 10.3389/fonc.2024.1320766. eCollection 2024.PMID: 38371623
Dankner M, Maritan SM, Priego N, Kruck G, Nkili-Meyong A, Nadaf J, Zhuang R, Annis MG, Zuo D, Nowakowski A, Biondini M, Kiepas A, Mourcos C, Le P, Charron F, Inglebert Y, Savage P, Théret L, Guiot MC, McKinney RA, Muller WJ, Park M, Valiente M, Petrecca K, Siegel PM. Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes. Neuro Oncol. 2024 Jun 3;26(6):1052-1066. doi: 10.1093/neuonc/noae013.PMID: 38271182
Cencic R, Im YK, Naineni SK, Moustafa-Kamal M, Jovanovic P, Sabourin V, Annis MG, Robert F, Schmeing TM, Koromilas A, Paquet M, Teodoro JG, Huang S, Siegel PM, Topisirovic I, Ursini-Siegel J, Pelletier J. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2318093121. doi: 10.1073/pnas.2318093121. Epub 2024 Jan 17.PMID: 38232291
Lewis K, La Selva R, Maldonado E, Annis MG, Najyb O, Cepeda Cañedo E, Totten S, Hébert S, Sabourin V, Mirabelli C, Ciccolini E, Lehuédé C, Choinière L, Russo M, Avizonis D, Park M, St-Pierre J, Kleinman CL, Siegel PM, Ursini-Siegel J. p66ShcA promotes malignant breast cancer phenotypes by alleviating energetic and oxidative stress. Redox Biol. 2024 Apr;70:103028. doi: 10.1016/j.redox.2024.103028. Epub 2024 Jan 5.PMID: 38211442
2023
Audet-Delage Y, St-Louis C, Minarrieta L, McGuirk S, Kurreal I, Annis MG, Mer AS, Siegel PM, St-Pierre J. Spatiotemporal modeling of chemoresistance evolution in breast tumors uncovers dependencies on SLC38A7 and SLC46A1. Cell Rep. 2023 Oct 31;42(10):113191. doi: 10.1016/j.celrep.2023.113191. Epub 2023 Oct 4.PMID: 37792528
Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, Solymoss E, Bui T, Kuasne H, Papavasiliou V, Lee CG, Kamle S, Siegel PM, Elias JA, Park M, Muller WJ. The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity. 2023 Dec 12;56(12):2755-2772.e8. doi: 10.1016/j.immuni.2023.11.002. Epub 2023 Nov 30.PMID: 38039967 Free article.
Desjardins-Lecavalier N, Annis MG, Nowakowski A, Kiepas A, Binan L, Roy J, Modica G, Hébert S, Kleinman CL, Siegel PM*, Costantino S*. Migration speed of captured breast cancer subpopulations correlates with metastatic fitness. J Cell Sci. 2023 Jun 14:jcs.260835. doi: 10.1242/jcs.260835. Epub ahead of print. PMID: 37313743.*Co-corresponding Authors.
Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, Dankner M, Fallah P, Doré S, Zuo D, Fiset B, Kloosterman DJ, Ramsay L, Wei Y, Lam S, Alsajjan R, Watson IR, Roldan Urgoiti G, Park M, Brandsma D, Senger DL, Chan JA, Akkari L, Petrecca K, Guiot MC, Siegel PM*, Quail DF*, Walsh LA*. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature. 2023 Feb;614(7948):555-563. doi: 10.1038/s41586-022-05680-3. Epub 2023 Feb 1. PMID: 36725935; PMCID: PMC9931580.*Co-corresponding Authors.
Sorin M, Rezanejad M, Karimi E, Fiset B, Desharnais L, Perus LJM, Milette S, Yu MW, Maritan SM, Doré S, Pichette É, Enlow W, Gagné A, Wei Y, Orain M, Manem VSK, Rayes R, Siegel PM, Camilleri-Broët S, Fiset PO, Desmeules P, Spicer JD, Quail DF, Joubert P, Walsh LA. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature. 2023 Feb;614(7948):548-554. doi: 10.1038/s41586-022-05672-3. Epub 2023 Feb 1. PMID: 36725934; PMCID: PMC9931585.
2022
Nowakowski A, Lahijanian Z, Panet-Raymond V, Siegel PM, Petrecca K, Maleki F, Dankner M. Radiomics as an emerging tool in the management of brain metastases. Neurooncol Adv. 2022 Sep 6;4(1):vdac141. doi: 10.1093/noajnl/vdac141. PMID: 36284932; PMCID: PMC9583687.
AM.Lazaratos, MG Annis, P.M. Siegel. GPNMB: a potent inducer of immunosuppression in cancer. Oncogene. 2022 Oct;41(41):4573-4590. doi: 10.1038/s41388-022-02443-2. Epub 2022 Sep 1. PMID: 36050467.
M. Biondini, A. Kiepas, L. El-Houjeiri, M.G. Annis, B.E.Hsu, A.M. Fortier, G. Morin, J.A. Martina, I. Sirois, A. Aguilar-Mahecha, T. Gruosso, S. McGuirk, A.A.N Rose, U.M. Tokat, R.M Johnson RM, O. Sahin, E. Bareke, J. St-Pierre, M. Park, M. Basik, J. Majewski, R. Puertollano, A. Pause, S. Huang, T. Keler, P.M. Siegel. (2022). HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. Oncogene. 41(12):1701-1717.
L. El-Houjeiri, M. Biondini, M. Paquette, H. Kuasne, A. Pacis, M. Park, P.M. Siegel, A.Pause. (2022). Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. J Clin Invest. 131(22): e144871.
2021
J. Huxham, S. Tabariès, P.M. Siegel. (2021). Afadin (AF6): A multi-domain scaffold protein with complex and contradictory roles in cancer progression. BioEssays. 43(1): e2000221.
M. Dankner, M. Caron, T. Al-Saadi, W. Yu, V. Ouellet, R. Ezzeddine, M.G. Annis, P.U. Le, J. Nadaf, N.S. Neubarth, P. Savage, D. Zuo, C.P. Couturier, J. Monlong, H. Djambazian, H. Altoukhi, G. Bourque, J. Ragoussis, R.J. Diaz, M. Park, M-C. Guiot, S. Lam, K. Petrecca* and P.M. Siegel*. (2021). Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases. Neuro-Oncology. Sep 1;23(9):1470-1480. *Co-corresponding Authors.
M. Dankner, S. Lam, T. Degenhard, L. Garzia, M-C Guiot, K. Petrecca, and P.M. Siegel. (2021). The underlying biology and therapeutic vulnerabilities of leptomeningeal metastases in adult solid cancers. Cancers. 13(4): 732.
O.A. Maguire, S.E. Ackerman, S.K. Szwed, A.V. Maganti, F. Marchildon, X. Huang, D.J. Kramer, A. Rosas-Villegas, R.G. Gelfer, L.E. Turner, V. Ceballos, A. Hejazi, B. Samborska, J.F. Rahbani, C.B. Dykstra, M.G. Annis, J-D. Luo, T.S. Carroll, C.S. Jiang, A.J. Dannenberg, P.M. Siegel, S.A. Tersey, R.G. Mirmira, L. Kazak, P. Cohen. (2021). Creatine mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer. Cell Metabolism. Mar 2;33(3):499-512.e6.
M. Paquette, L. El-Houjeiri, L.C. Zirden, P. Puustinen, P. Blanchette, H. Jeong, K. Dejgaard, P.M. Siegel, A. Pause (2021). AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3. Autophagy. Dec;17(12):3957-3975.
S. Tabariès, M.G. Annis, A. Lazaris, S. Petrillo, A. Abdellatif, V. Palmieri, J. Chabot, R. Johnson, S. van Laere, C. Verhoef, Y. Hachem, S. Yumeen, N. Meti, A. Omeroglu, G. Altinel, Z-H. Gao, D. Grünhagen, P. Vermeulen, P. Metrakos*, P.M. Siegel*. (2021). Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Comm Biol. 4(1) 657. *Co-corresponding Authors.
S. Totten, Y. Im, O. Najyb, E.C. Canedo, A. Nguyen, S. Hebert, R. Ahn, R. La Selva, V. Sabourin, C. Martinez, P. Savage, H. Kuasne, D. Avizonis, N.S. Martinez, C. Chabot, A. Aguilar-Mahecha, M-L. Goulet, M. Dankner, M. Witcher , K. Petrecca, M. Basik, M. Pollak, I. Topisirovic, R. Lin, P.M. Siegel , C. Kleiman, M. Park, J. St-Pierre and J. Ursini-Siegel. (2021). STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nat Comm. 12(1) 3299.
S. McGuirk, Y. Audet-Delage, C. St-Louis, M.G. Annis, Y. Xue, M. Vernier, K. Zhao, L. Minarrieta, D. Patten, G. Morin, C.M.T. Greenwood, V. Giguère, S. Huang, P.M. Siegel and J. St-Pierre. (2021). Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. Elife. 10: 265150.
M. Rada, A. Lamoureux, S. Petrillo, S. Tabariès, P.M. Siegel, A. Reynolds, A. Lazaris and P Metrakos. (2021). Runt Related Transcription Factor-1 (RUNX1) plays a central role in vessel co-option of colorectal cancer liver metastases. Comm Biology. 4(1): 950.
M. Paquette, M. Yan, L. El-Houjeiri, M. Biondini, J.M.J. Ramirez-Reyes, C.R. Dufour, H. Jeong, A. Pacis, V. Giguère, J.L. Estall, P.M. Siegel, A. Pause and E. Audet-Walsh. (2021). Loss of hepatic FLCN protects against fibrosis and inflammation by activating autophagy pathways. Sci Reports. 11(1): 21268.
L. El-Houjeiri, M. Biondini, M. Paquette, H. Kuasne, A. Pacis, M. Park, P.M. Siegel* and A. Pause*. (2021). Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. J Clin. Invest. 131(22). E144871. *Co-corresponding Authors.
2020
K. Lewis, A. Kiepas, J. Hudson, J. Senecal, J.R. Ha, E. Voorand, M.G. Annis, V. Sabourin, R. Ahn, R. La Selva, S. Tabariès, B.E. Hsu, M.J. Siegel, M. Dankner, E.C. Canedo, M. Lajoie, I.R. Watson, C.M. Brown, P.M. Siegel* and J. Ursini-Siegel*. (2020). p66ShcA functions as a contextual promoter of breast cancer metastasis. Breast Cancer Research. 22(1): 7. *Co-corresponding Authors.
A. Kiepas, E. Voorand, F. Mubaid, P.M. Siegel and C.M. Brown. (2020). Optimizing live-cell fluorescence imaging conditions to minimize phototoxicity. J Cell Sci. 133. Jcs242834.
B.E. Hsu, J. Roy, J. Mouhanna, R.F. Rayes, L. Ramsay, S. Tabariès, M.G. Annis, I.R. Watson, J.D. Spicer, S. Costantino and P.M. Siegel. (2020). C3a elicits unique migratory responses on immature low-density neutrophils. Oncogene. 39(12): 2612-2623.
A. Kiepas, E. Voorand, J. Senecal, R. Ahn, M.G. Annis, K. Jacquet, G. Tali, N. Bisson, J. Ursini-Siegel, P.M. Siegel* and C.M. Brown*. (2020). The ShcA adaptor protein cooperates with LPP to mediate adhesion dynamics and invadopodia formation. J. Biol. Chem. 295(31): 10535-10559. *Co-corresponding Authors.
P. Savage, A. Pacis, H. Kuasne, L. Liu, D. Lai, A. Wan, M. Dankner, C. Martinez, V. Munoz-Ramos, V. Pilon, A. Monast, H. Zhao, M. Souleimanova, M. Annis, A. Aguilar-Mahecha, J. Lafleur, N. Bertos, J. Asselah, N. Bouganim, K. Petrecca, P.M. Siegel, A. Omeroglu, S. Shah, A. Apericio, M. Basik, S. Meterissian and M. Park. (2020). Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Comm Biol. 3(1): 310.
B.E. Hsu, Y. Shen and P.M. Siegel. (2020). Neutrophils: Orchestrators of the Malignant Phenotype. Frontiers in Immunology. 11:1178.
2019
Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabariès S, Gettemans J, Siegel PM, Komarova SV. Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. Transl Oncol. 2019 Mar.
Tabariès S, McNulty A, Ouellet V, Annis MG, Dessureault M, Vinette M, Hachem Y, Lavoie B, Omeroglu A, Simon HG, Walsh LA, Kimbung S, Hedenfalk I, Siegel PM. Afadin cooperates with Claudin-2 to promote breast cancer metastasis. Genes Dev. 2019 Feb 1.
Maric G, Annis MG, MacDonald PA, Russo C, Perkins D, Siwak DR, Mills GB, Siegel PM. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity. Oncogene. 2019 Jun.
Dankner M, Ouellet V, Communal L, Schmitt E, Perkins D, Annis MG, Barrès V, Caron C, Mes-Masson AM, Saad F, Siegel PM; Canadian Prostate Cancer Biomarker Network. CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.Am J Pathol. 2019 Jul.
Yoshie H, Koushki N, Molter C, Siegel PM, Krishnan R, Ehrlicher AJ. High Throughput Traction Force Microscopy Using PDMS Reveals Dose-Dependent Effects of Transforming Growth Factor-β on the Epithelial-to-Mesenchymal Transition. J Vis Exp. 2019 Jun 1.
Hsu BE, Tabariès S, Johnson RM, Andrzejewski S, Senecal J, Lehuédé C, Annis MG, Ma EH, Völs S, Ramsay L, Froment R, Monast A, Watson IR, Granot Z, Jones RG, St-Pierre J, Siegel PM. (2019). Immature Low-Density Neutrophils Exhibit Metabolic Flexibility that Facilitates Breast Cancer Liver Metastasis. Cell Rep. 2019 Jun 25.
Choudhury SR, Babes L, Rahn JJ, Ahn BY, Goring KR, King JC, Lau A, Petri B, Hao X, Chojnacki AK, Thanabalasuriar A, McAvoy EF, Tabariès S, Schraeder C, Patel KD, Siegel PM, Kopciuk KA, Schriemer DC, Muruve DA, Kelly MM, Yipp BG, Kubes P, Robbins SM, Senger DL.Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver.Cell. 2019 Aug 22.
Dankner M, Senecal J, Neubarth NS, Bertos N, Park M, Issa-Chergui B, Asselah J, Siegel PM, Bouganim N. A survey of healthcare professionals and oncology patients at the McGill University Health Centre reveals enthusiasm for establishing a postmortem rapid tissue donation program. Current Oncology. August 1, 2019.
S. Zhou, S.D. da Silva, P. Siegel and A. Philip. (2019). CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells. Scientific Reports. 9(1): 16317.
2018
James-Bhasin M, Siegel PM, Nazhat SN. A Three-Dimensional Dense Collagen Hydrogel to Model Cancer Cell/Osteoblast Interactions. J Funct Biomater. 2018 Dec 12.
Ashktorab H, Rahi H, Nouraie M, Shokrani B, Lee E, Haydari T, Laiyemo AO, Siegel P, Brim H. (2018). GPNMB methylation: a new marker of potentially carcinogenic colon lesions.BMC Cancer. 2018 Nov 6.
Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I. (2018). Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.Cell Metab. 2018 Sep 17.
Andrzejewski S, Siegel PM, St-Pierre J. (2018). Metabolic Profiles Associated With Metformin Efficacy in Cancer.Front Endocrinol (Lausanne). 2018 Aug 21.
Poffenberger MC, Metcalfe-Roach A, Aguilar E, Chen J, Hsu BE, Wong AH, Johnson RM, Flynn B, Samborska B, Ma EH, Gravel SP, Tonelli L, Devorkin L, Kim P, Hall A, Izreig S, Loginicheva E, Beauchemin N, Siegel PM, Artyomov MN, Lum JJ, Zogopoulos G, Blagih J, Jones RG. (2018). LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis. Science. 2018 Jul 27.
Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN. (2018). Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clin Cancer Res. 2018 Jun 14.
Bernier C, Soliman A, Gravel M, Dankner M, Savage P, Petrecca K, Park M, Siegel PM, Shore GC, Roulston A. (2018). DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs. 2018 Sep;29.
Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A. (2018). EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene. 2018 Jul.
Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. (2018). Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018 Jun.
Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, Del Rincon SV, Miller WH Jr., Ramón Y Cajal S, Park M, Jones RG, Piccirillo CA, Siegel PM, Sonenberg N. (2018). Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. Proc Natl Acad Sci U S A. 2018 Feb 20.
Annis MG, Ouellet V, Rennhack JP, L'Esperance S, Rancourt C, Mes-Masson AM, Andrechek ER, Siegel PM. (2018) .Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.Breast Cancer Res. 2018 Jan 30.
2017
Ngan E, Kiepas A, Brown CM, Siegel PM. (2017). Emerging roles for LPP in metastatic cancer progression. J Cell Commun Signal. 2017 Oct 13.
Andrzejewski S, Klimcakova E, Johnson RM, Tabariès S, Annis MG, McGuirk S, Northey JJ, Chénard V, Sriram U, Papadopoli DJ, Siegel PM, St-Pierre J. (2017). PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.Cell Metab. 2017 Nov 7.
Rose AAN, Biondini M, Curiel R, Siegel PM.(2017). Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.Pharmacol Ther. 2017 Nov.
Ngan E, Stoletov K, Smith HW, Common J, Muller WJ, Lewis JD, Siegel PM. (2017). LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis.Nat Commun. 2017 Apr 24.
Hsu BE, Siegel PM. (2017). Expanding the armamentarium for neutrophil-mediated angiogenesis. Hepatology. 2017 Jun.
He Y, Northey JJ, Pelletier A, Kos Z, Meunier L, Haibe-Kains B, Mes-Masson AM, Côté JF, Siegel PM, Lamarche-Vane N.(2017). The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. Oncogene. 2017 Jun.
Tabariès S, Siegel PM. (2017). Role of Claudins in Cancer Metastasis. Oncogene. 2017 Mar.
Nooh A, Zhang YL, Sato D, Rosenzweig DH, Tabariès S, Siegel P, Barralet JE, Weber MH. (2017). Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. J Bone Oncol. 2017 Jan 13.
2016
Wieczorek M, Tcherkezian J, Bernier C, Prota AE, Chaaban S, Rolland Y, Godbout C, Hancock MA, Arezzo JC, Ocal O, Rocha C, Olieric N, Hall A, Ding H, Bramoullé A, Annis MG, Zogopoulos G, Harran PG, Wilkie TM, Brekken RA, Siegel PM, Steinmetz MO, Shore GC, Brouhard GJ, Roulston A. (2016). The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci Transl Med. 2016 Nov 16.
Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. (2016). MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clin Cancer Res. 2016 Dec 15.
Rajadurai CV, Havrylov S, Coelho PP, Ratcliffe CD, Zaoui K, Huang BH, Monast A, Chughtai N, Sangwan V, Gertler FB, Siegel PM, Park M. (2016). 5'-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. J Cell Biol. 2016 Sep 12.
Lehuédé C, Dupuy F, Rabinovitch R, Jones RG, Siegel PM. (2016). Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis. Cancer Res. 2016 Sep 15.
Pedanou VE, Gobeil S, Tabariès S, Simone TM, Zhu LJ, Siegel PM, Green MR. (2016). The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. Elife. 2016 Jul 29.
Ha JR, Siegel PM, Ursini-Siegel J.(2016). The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness. J Cell Biochem. 2016 Sep.
Fernandes R, Siegel P, Komarova S, Hilton J, Addison C, Ibrahim MF, Werier J, Dennis K, Singh G, Amir E, Jarvis V, Emmenegger U, Mazzarello S, Clemons M. (2016). Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS). J Bone Oncol. 2016 Feb 23.
Singh SR, Rameshwar P, Siegel P.(2016).Targeting tumor microenvironment in cancer therapy.Cancer Lett. 2016 Sep 28.
Cyr-Depauw C, Northey JJ, Tabariès S, Annis MG, Dong Z, Cory S, Hallett M, Rennhack JP, Andrechek ER, Siegel PM.(2016).Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion. Mol Cell Biol. 2016 May 2.
2015
Ursini-Siegel J, Siegel PM. (2015). The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Lett. 2015 Nov 11.
Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, Negi S, Awan Z, Aikin R, Kwan J, Amre R, Tabaries S, Hassanain M, Seidah NG, Maluccio M, Siegel P, Metrakos P. (2015). Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015 Dec 16.
Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM. (2015). PDK1-Dependent metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell metab. 2015 Sep 9.
Rafiei S, Tiedemann K, Tabariès S, Siegel PM, Komarova SV. (2015). Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.Cancer Lett. 2015 Jun 1;361(2):262-70.
Tabariès S, Annis MG, Hsu BE, Tam CE, Savage P, Park M, Siegel PM. (2015).Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.Oncotarget. 2015 Apr 20;6(11):9476-87.
Wang N, Rayes RF, Elahi SM, Lu Y, Hancock MA, Massie B, Rowe GE, Aomari H, Hossain S, Durocher Y, Pinard M, Tabariès S, Siegel PM, Brodt P.(2015). The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis.Mol Cancer Ther. 2015 Apr;14(4):982-93.
Li H, Bergeron S, Annis MG, Siegel PM, Juncker D. (2015).Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray.Mol Cell Proteomics. 2015 Apr;14(4):1024-37.
Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, Carmona E, Tam CE, Mes-Masson AM, Siegel PM.(2015). Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res. 2015 Mar;27;17:45
Maric G, Annis MG, Dong Z, Rose AA, Ng S, Perkins D, MacDonald PA, Ouellet V, Russo C, Siegel PM. (2015).GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.Oncogene. 2015 Mar 16.
Pettersson F, Del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Siegel PM, Miller WH Jr. (2015). Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.Cancer Res. 2015 Mar 15;75(6):1102-12.
2014
Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L. (2014). Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.J Clin Oncol. 2014 Nov 10;32(32):3619-25.
Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, Corcoran A, Jones DT, Sturm D, Johann P, Tomita T, Goldman S, Nagib M, Bendel A, Goumnerova L, Bowers DC, Leonard JR, Rubin JB, Alden T, Browd S, Geyer JR, Leary S, Jallo G, Cohen K, Gupta N, Prados MD, Carret AS, Ellezam B, Crevier L, Klekner A, Bognar L, Hauser P, Garami M, Myseros J, Dong Z, Siegel PM, Malkin H, Ligon AH, Albrecht S, Pfister SM, Ligon KL, Majewski J, Jabado N, Kieran MW.(2014). Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May;46(5):462-6
Guilbert C, Annis MG, Dong Z, Siegel PM, Miller WH Jr, Mann KK.(2014). Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer. PLoS One. 2013 Dec 31;8(12):e85995.
Kleinman CL, Gerges N, Papillon-Cavanagh S, Sin-Chan P, Pramatarova A, Quang DA, Adoue V, Busche S, Caron M, Djambazian H, Bemmo A, Fontebasso AM, Spence T, Schwartzentruber J, Albrecht S, Hauser P, Garami M, Klekner A, Bognar L, Montes JL, Staffa A, Montpetit A, Berube P, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel PM, Duchaine T, Perotti C, Fleming A, Faury D, Remke M, Gallo M, Dirks P, Taylor MD, Sladek R, Pastinen T, Chan JA, Huang A, Majewski J, Jabado N.(2014). Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014 Jan;46(1):39-44
2013
Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C, Dong Z, Siwak DR, Annis MG, Mills GB, Muller WJ, Siegel PM, Jones RG.(2013). LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer Metab. 2013 Aug 14;1(1):18
Maric G, Rose AA, Annis MG, Siegel PM.(2013). Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther. 2013 Jul 9;6:839-52
Ahn R, Sabourin V, Ha JR, Cory S, Maric G, Im YK, Hardy WR, Zhao H, Park M, Hallett M, Siegel PM, Pawson T, Ursini-Siegel J.(2013). The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression. Cancer Res. 2013 Jul 15;73(14):4521-32
Ngan E, Northey JJ, Brown CM, Ursini-Siegel J, Siegel PM.(2013). A complex containing LPP and α-Actinin mediates TGFβ-induced migration and invasion of ErbB2-expressing breast cancer cells. J Cell Sci. 2013 Feb 27
Northey JJ, Dong Z, Ngan E, Kaplan A, Hardy WR, Pawson T, Siegel PM.(2013). Distinct phosphotyrosine-dependent functions of the ShcA adaptor protein are required for transforming growth factor β (TGFβ)-induced breast cancer cell migration, invasion, and metastasis. J Biol Chem. 2013 Feb 15;288(7):5210-22
Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG.(2013). AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013 Jan 8;17(1):113-24
Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Komarova SV, Siegel PM.(2012). ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res. 2012 Nov 22;14(6):R149
Tabariès S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM.(2012). Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes.Mol Cell Biol. 2012 Aug;32(15):2979-91
Ouellet V, Siegel PM. (2012). CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. J Cell Commun Signal. 2012 June;6(2):73-85
Fathers KE, Bell ES, Rajadurai CV, Cory S, Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, Grosset AA, Gaboury L, Hallet M, Siegel P, Park M. (2012). Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res. 2012 May 8;14(3):R74
Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.. Nature. 2012 Jan 29;482(7384):226-31
Tabaries S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM. (2012). Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol.
Ouellet V, Siegel PM.(2012). CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis.. J Cell Commun Signal Jun;6(2):73-85.
Li J, Karaplis AC, Huang DC, Siegel PM, Camirand A, Yang XF, Muller WJ, Kremer R. (2011). PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy targets. J Clin Invest. Dec 1;121(12):4655-69.
Labelle-Côté M, Dusseault J, Ismaïl S, Picard-Cloutier A, Siegel PM, Larose L.(2011). Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo. BMC Cancer. Oct 12;11:443.
Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komarova SV, Siegel PM. (2011). CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol. 2011 May;178(5):2377-88.
S. Tabariès, Z. Dong, M.G. Annis, A. Omeroglu, F. Pepin, V. Ouellet, C. Russo, M. Hassanain, P. Metrakos, Z. Diaz, M. Basik, N. Bertos, M. Park, C. Guettier, R. Adam, M. Hallett and P.M. Siegel (2011). Claudin-2 enhances integrin-mediated breast cancer cell adhesion and promotes liver metastasis. Oncogene 30, 1318-1328.
Y.He, J.J. Northey, M. Primeau, R.D. Machado, R. Trembath, P.M. Siegel and N. Lamarche-Vane (2011). CdGAP is required for Transforming Growth Factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Oncogene 30, 1032-1045
S. Hassan, M. Buchanan, L. Gaboury, W. Muller, A. Alsawafi, A. Mourskaia, P. Siegel and M. Basik. (2011). CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J Cancer, 129:1, 225–232.
A. Bemmo, C. Dias, A.A.N. Rose, C. Russo, P. Siegel and J. Majewski. (2010). Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities. PLoS One 5(8). pii: e11981.
M. Demers, A.A.N. Rose, A.A. Grosset, L. Gaboury, P.M. Siegel, Y. St-Pierre. (2010) Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am. J. Path. 176(6):3023-3031.
A.A.N. Rose, P.A. MacDonald, Z. Dong, C. Russo, N.R. Bertos, R. Simantov, M. Park and P.M. Siegel (2010). GPNMB/Osteoactivin is an independent prognostic indicator of recurrence and a potential therapeutic target in breast cancer. Clin. Cancer Res. 16(7): 2147-2156.
P.M. Siegel and W.J. Muller (2010). Transcription Factor Regulatory Networks in Mammary Epithelial Development and Tumorigenesis. Oncogene. 29(19):2753-2759.
A.A. Rose and P.M. Siegel (2010). Emerging Therapeutic Targets in Breast Cancer Bone Metastasis. Future Oncology 6(1):55-74.
K. Tiedemann, O. Hussein, G. Sadvakassova, Y. Guo, P.M. Siegel, and S.V. Komarova. (2009). Breast cancer derived factors stimulate osteoclastogenesis through synergy between the Ca2+/PKC and TGFbeta/MAPK signaling pathways. J. Biol. Chem. 284(48):33662-33670.
Kristin Roovers, Simona Wagner, Christopher J. Storbeck, Paul O’Reilly, Jason Northey, Juliann Chmielecki, William J. Muller, Peter M. Siegel and Luc A. Sabourin (2009). The Ste20-like kinase SLK is required for ErbB2-driven motility of mammary epithelial cells. Oncogene 28(31):2839-2848.
Dydensborg, AB, Rose, AAN, Grote, D, Paquet, M, Siegel, PM and Bouchard, M. (2009). GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis independently of its effects on cell differentiation. Oncogene 28(29): 2634-2642.
A.A. Mourskaia, Z. Dong, S. Ng, M. Banville, J. Zwaagstra, M. O'Connor-McCourt, P.M. Siegel. (2009). Transforming growth factor-β1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene. 28:1005-15.
J.J. Northey, J. Chmielecki, E. Ngan, C. Russo, M.G. Annis, W. J. Muller, P.M. Siegel. (2008). Signaling through ShcA is required for TGF-beta and Neu/ErbB-2 induced breast cancer cell motility and invasion. Mol. Cell Biol. 28(10):3162-76.
A.A.N. Rose, F. Pepin, C. Russo, J.E. Abou Khalil, M. Hallet, P.M. Siegel. (2007). Osteoactivin Promotes Breast Cancer Metastasis to Bone. Mol. Cancer Res. 5(10):1001-14.
A.A. Mourskaia, J.J.Northey, P.M. Siegel. (2007). Targeting aberrant TGF-β signaling in pre-clinical models of cancer. Anticancer Agents Med.Chem. 7(5):504-514
A.A.N. Rose and P.M. Siegel. (2006). Breast Cancer-Derived Factors Facilitate Osteolytic Bone Metastasis. Bull. Cancer. 93(9): 931-943
G.P. Gupta, A.J. Minn, Y. Kang, P.M. Siegel, I. Serganova, C. Cordon-Cardo, A.B. Olshen, W.L. Gerald and J. Massague (2005). Identifying Site-specific Metastasis Genes and Functions. Cold Spring Harb Symp Quant Biol. 70:1-10.
A.J. Minn, G.P. Gupta, P.M. Siegel, P.D. Bos , W. Shu, D.D. Giri, A. Viale, A.B. Olshen, W.L. Gerald and J. Massagué. (2005). Genes that mediate breast cancer metastasis to lung. Nature. 436: 518-524.
P.M. Siegel and J. Massagué. (2003). Cytostatic and apoptotic actions of TGF-b in homeostasis and cancer. Nat. Rev. Cancer. 3: 807-820.
P.M. Siegel, W. Shu and J. Massagué. (2003). Mad Upregulation and Id2 Repression Accompany TGF-b Mediated Epithelial Cell Growth Suppression. J. Biol. Chem. 278: 35444-35450.
P.M. Siegel, W. Shu, R.D. Cardiff, W.J. Muller and J. Massagué. (2003). Transforming Growth Factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA. 100: 8430-8435.
Y. Kang, P.M. Siegel, W. Shu, M. Drobnjak, S.M. Kakonen, C. Cardon-Cardo, T.A. Guise and J. Massagué. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3: 537-549.
C-R. Chen, Y. Kang, P.M. Siegel and J. Massagué. (2002). E2F4/5 and p107 as Smad Cofactors linking the TGFb Receptor to c-myc repression. Cell 110: 19-32.
::
Click for complete Peter Siegel Ph.D. PUBMED
